Thorneloe Kevin S, Maruyama Yoshiaki, Malcolm A Todd, Light Peter E, Walsh Michael P, Cole William C
Smooth Muscle Research Group and Canadian Institutes of Health Research Group in Regulation of Vascular Contractility, University of Calgary, Calgary, Alberta, Canada.
J Physiol. 2002 May 15;541(Pt 1):65-80. doi: 10.1113/jphysiol.2002.018101.
The molecular identity of smooth muscle ATP-sensitive K(+) channels (K(ATP)) is not established with certainty. Patch clamp methods were employed to determine if recombinant K(ATP) channels composed of Kir6.1 and SUR2B subunits expressed by human embryonic kidney (HEK293) cells share an identical modulation by protein kinase C (PKC) with the vascular K(NDP) subtype of K(ATP) channel. The open probability of Kir6.1/SUR2B channels was determined before and after sequential exposure to pinacidil (50 microM) and the combination of pinacidil and phorbol 12,13-dibutyrate (PdBu; 50 nM). Treatment with PdBu caused a decline in channel activity, but this was not seen with an inactive phorbol ester, 4 alpha-phorbol 12,13-didecanoate (PdDe; 50 nM). Angiotensin II (0.1 microM) induced a similar inhibition of Kir6.1/SUR2B channels in cells expressing angiotensin AT(1) receptors. The effects of PdBu and angiotensin II were blocked by the PKC inhibitor, chelerythrine (3 microM). Purified PKC inhibited Kir6.1/SUR2B activity (in 0.5 mM ATP/ 0.5 mM ADP), and the inhibition was blocked by a specific peptide inhibitor of PKC, PKC(19-31). In contrast, PdBu increased the activity of recombinant K(ATP) channels composed of Kir6.2 and SUR2B, or the combination of Kir6.1, Kir6.2 and SUR2B subunits. The results indicate that the modulation by PKC of Kir6.1/SUR2B, but not Kir6.2/SUR2B or Kir6.1-Kir6.2/SUR2B channel gating mimics that of native vascular K(NDP) channels. Physiological inhibition of vascular K(ATP) current by vasoconstrictors which utilize intracellular signalling cascades involving PKC is concluded to involve the modulation of K(NDP) channel complexes composed of four Kir6.1 and their associated SUR2B subunits.
平滑肌ATP敏感性钾通道(K(ATP))的分子特性尚未完全确定。采用膜片钳方法来确定由人胚肾(HEK293)细胞表达的、由Kir6.1和SUR2B亚基组成的重组K(ATP)通道,与血管K(ATP)通道的K(NDP)亚型在蛋白激酶C(PKC)调节方面是否具有相同的特性。在先后暴露于吡那地尔(50微摩尔)以及吡那地尔与佛波醇12,13 - 二丁酸酯(PdBu;50纳摩尔)的组合之前和之后,测定Kir6.1/SUR2B通道的开放概率。用PdBu处理导致通道活性下降,但用无活性的佛波醇酯4α - 佛波醇12,13 - 二癸酸酯(PdDe;50纳摩尔)处理时未观察到这种情况。血管紧张素II(0.1微摩尔)在表达血管紧张素AT(1)受体的细胞中诱导了对Kir6.1/SUR2B通道的类似抑制作用。PdBu和血管紧张素II的作用被PKC抑制剂白屈菜红碱(3微摩尔)阻断。纯化的PKC抑制Kir6.1/SUR2B活性(在0.5毫摩尔ATP/0.5毫摩尔ADP中),并且这种抑制作用被PKC的一种特异性肽抑制剂PKC(19 - 31)阻断。相反,PdBu增加了由Kir6.2和SUR2B组成的重组K(ATP)通道,或由Kir6.1、Kir6.2和SUR2B亚基组合而成的通道的活性。结果表明,PKC对Kir6.1/SUR2B通道门控的调节作用,而不是对Kir6.2/SUR2B或Kir6.1 - Kir6.2/SUR2B通道的调节作用,模拟了天然血管K(NDP)通道的调节作用。得出结论,利用涉及PKC的细胞内信号级联反应的血管收缩剂对血管K(ATP)电流的生理性抑制作用,涉及由四个Kir6.1及其相关的SUR2B亚基组成的K(NDP)通道复合物的调节。